Mapping of immune responses following wild-type and mutant ABeta42 plasmid or peptide vaccination in different mouse haplotypes and HLA Class II transgenic mice

Vaccine

Volumn 24, Issue 21, 2006, Pages 4630-4639

  Kutzler, Michele A ^a   Cao, Chuanhai ^b,c   Bai, Yun ^c   Dong, HuiQin ^c   Choe, Philip Y ^a   Saulino, Vera ^a   McLaughlin, Laura ^c   Whelan, Alex ^c   Choo, Andrew Y ^a   Weiner, David B ^a   Ugen, Kenneth E ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Research Institute   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

ABeta42; Dutch and Flemish mutations; Mouse haplotypes

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN[1-42]; HLA ANTIGEN CLASS 2;

ALZHEIMER DISEASE; ANTIBODY RESPONSE; ARTICLE; BRAIN HEMORRHAGE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; HAPLOTYPE; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

AMINO ACID SEQUENCE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODY FORMATION; CD8-POSITIVE T-LYMPHOCYTES; CLONING, MOLECULAR; DNA; ENZYME-LINKED IMMUNOSORBENT ASSAY; HAPLOTYPES; HISTOCOMPATIBILITY ANTIGENS CLASS II; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; PEPTIDES; PLASMIDS; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 33747094107     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.08.036     Document Type: Article

References (28)

1. Golde T.E., Eckman C.B., and Younkin S.G. Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim Biophys Acta 1502 1 (2000) 172-187
2. Yankner B.A. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 16 5 (1996) 921-932
3. Schenk D., Barbour R., Dunn W., Gordon G., Gradeja H., Guido T., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 6740 (1999) 173-177
4. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 6815 (2000) 982-985
5. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408 6815 (2000) 979-982
6. Bacskai B.J., Kajdasz S.T., Christie R.H., Carter C., Games D., Seubert P., et al. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 7 3 (2001) 369-372
7. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6 8 (2000) 916-919
8. Kotilinek L.A., Bacskai B., Westerman M., Kawarabayashi T., Younkin L., Hyman B.T., et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 22 15 (2002) 6331-6335
9. Hock C., Konietzko U., Papassotiropoulos A., Wollmer A., Streffer J., Von Rotz R.C., et al. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer's disease. Nat Med 8 11 (2002) 1270-1275
10. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Muller-Tillmans B., et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38 4 (2003) 547-554
11. Kumar-Singh S., Julliams A., Nuydens R., Ceuterick C., Labeur C., Serreels S., et al. In vitro studies of Flemish, Dutch, and wild-type beta-amyloid provide evidence for two-staged neurotoxicity. Neurobiol Dis 11 2 (2002) 330-340
12. Hendriks L., van Duijn C.M., Cras P., Cruts M., van Hul W., van Harskamp F., et al. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nat Genet 1 3 (1992) 218-221
13. Levy E., Carman M.D., Fernandez-Madrid I.J., Power M.D., Lieberburg I., van Duinen S.G., et al. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage. Dutch Type Sci 248 4959 (1990) 1124-1126
14. Dickey C.A., Morgan D.G., Kudchodkar S., Weiner D.B., Bai Y., Cao C., et al. Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated beta-amyloid 1-42 peptide. DNA Cell Biol 20 11 (2001) 723-729
15. Cao C., Dickey C., Wilcock D., Bai Y., Gordon M.N., and Morgan D. Characterization of amyloid beta vaccination strategies in mice. In: Selkoe D.J., and Christen Y. (Eds). Immunization against Alzheimer's Disease and other neurodegenerative disorders, Vol. Fondation IPSEN Pour La Recherche Therapeutique (2003), Springer-Verlag, Berlin, Heidelberg 21-31
16. Li Q., Cao C., Chackerian B., Schiller J., Gordon M., Ugen K.E., et al. Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice. BMC Neurosci 5 1 (2004) 21
17. Das P., Chapoval S., Howard V., David C.S., and Golde T.E. Immune responses against Abeta1-42 in HLA class II transgenic mice: implications for Abeta1-42 immune-mediated therapies. Neurobiol Aging 24 7 (2003) 969-976
18. Cribbs D.H., Ghochikyan A., Vasilevko V., Tran M., Petrushina I., Sadzikava N., et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 15 4 (2003) 505-514
19. Bard F., Barbour R., Cannon C., Carretto R., Fox M., Games D., et al. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA 100 4 (2003) 2023-2028
20. Town T., Tan J., Sansone N., Obregon D., Klein T., and Mullan M. Characterization of murine immunoglobulin G antibodies against human amyloid-beta1-42. Neurosci Lett 307 2 (2001) 101-104
21. Lemere C.A., Maron R., Selkoe D.J., and Weiner H.L. Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease. DNA Cell Biol 20 11 (2001) 705-711
22. Lemere C.A., Maron R., Spooner E.T., Grenfell T.J., Mori C., Desai R., et al. Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann NY Acad Sci 920 (2000) 328-331
23. Petrushina I., Tran M., Sadzikava N., Ghochikyan A., Vasilevko V., Agadjanyan M.G., et al. Importance of IgG2c isotype in the immune response to beta-amyloid in amyloid precursor protein/transgenic mice. Neurosci Lett 338 1 (2003) 5-8
24. McLaurin J., Cecal R., Kierstead M.E., Tian X., Phinney A., Manea M., et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 8 11 (2002) 1263-1269
25. Miller D.L., Currie J.R., Mehta P.D., Potempska A., Hwang Y.W., and Wegiel J. Humoral immune response to fibrillar beta-amyloid peptide. Biochemistry 42 40 (2003) 11682-11692
26. Solomon B. Generation of anti-beta-amyloid antibodies via phage display technology towards Alzheimer's disease vaccination. Vaccine 23 17-18 (2005) 2327-2330
27. Frenkel D., Dori M., and Solomon B. Generation of anti-beta-amyloid antibodies via phage display technology. Vaccine 22 19 (2004) 2505-2508
28. Lavie V., Becker M., Cohen-Kupiec R., Yacoby I., Koppel R., Wedenig M., et al. EFRH-phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris water maze trials. J Mol Neurosci 24 1 (2004) 105-113